Monthly Archives: September 2013

Heads up for the European Cancer Congress in Amsterdam

2020-03-02T20:08:40+00:00September 24th, 2013|Categories: News|Tags: |

Clinical Trial Insights The annual European meeting offers insights into new data from ongoing clinical trials as well as a chance to discuss the implications of recently reported trial outcomes presented a few short months ago at ASCO. Pennside has reviewed the program in detail and we offer our assessment of key presentations at the meeting for drug developers and biotech.   Our Assessment of ESMO Key Presentations: CRC Analysis of [...]

Comments Off on Heads up for the European Cancer Congress in Amsterdam

Do We Need Phase III Randomized Controlled Trials for EVERYTHING?

2020-02-28T15:57:21+00:00September 23rd, 2013|Categories: Blog|Tags: , , |

Targeted therapy agents In clinical trials of targeted therapy agents, sometimes the target is such a crucial driver of the neoplastic process, that its inhibition is able to stop the growing tumor in its tracks. This appears to be the case for some recently approved agents such as vemurafenib for BRAF V600E melanoma and crizotinib for ALK+ NSCLC. Careful screening of patients for these mutations ensures the likelihood of improved [...]